Zoetis Inc. (NYSE:ZTS) Stock Position Raised by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 0.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 20,604 shares of the company’s stock after acquiring an additional 153 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Zoetis were worth $4,067,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. FinTrust Capital Advisors LLC boosted its position in shares of Zoetis by 42.1% in the third quarter. FinTrust Capital Advisors LLC now owns 260 shares of the company’s stock worth $45,000 after buying an additional 77 shares during the period. Raymond James Financial Services Advisors Inc. boosted its position in shares of Zoetis by 6.3% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 165,588 shares of the company’s stock worth $28,809,000 after buying an additional 9,757 shares during the period. Stratos Wealth Advisors LLC acquired a new stake in shares of Zoetis in the third quarter worth $209,000. Independent Advisor Alliance boosted its position in shares of Zoetis by 9.3% in the third quarter. Independent Advisor Alliance now owns 2,509 shares of the company’s stock worth $437,000 after buying an additional 213 shares during the period. Finally, Groesbeck Investment Management Corp NJ boosted its position in shares of Zoetis by 8.2% in the third quarter. Groesbeck Investment Management Corp NJ now owns 3,300 shares of the company’s stock worth $574,000 after buying an additional 250 shares during the period. 92.80% of the stock is owned by institutional investors.

Insider Activity

In related news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $173.33, for a total transaction of $159,983.59. Following the sale, the executive vice president now directly owns 15,723 shares of the company’s stock, valued at $2,725,267.59. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last ninety days, insiders have sold 2,209 shares of company stock valued at $371,293. 0.16% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ZTS shares. Barclays cut their price objective on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 23rd. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. The Goldman Sachs Group increased their price objective on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Piper Sandler reiterated an “overweight” rating and set a $195.00 price objective (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Finally, Stifel Nicolaus cut their price objective on Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $216.13.

Zoetis Stock Down 0.1 %

NYSE ZTS traded down $0.16 during trading on Friday, hitting $167.07. 3,007,125 shares of the company traded hands, compared to its average volume of 4,607,073. The company has a market capitalization of $76.41 billion, a P/E ratio of 32.19, a PEG ratio of 2.62 and a beta of 0.86. The business has a fifty day simple moving average of $168.88 and a 200 day simple moving average of $178.84. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.04. The company had revenue of $2.19 billion for the quarter, compared to the consensus estimate of $2.14 billion. Zoetis had a return on equity of 50.74% and a net margin of 27.38%. The firm’s revenue was up 9.5% compared to the same quarter last year. During the same period last year, the business posted $1.31 earnings per share. As a group, sell-side analysts predict that Zoetis Inc. will post 5.78 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be given a $0.432 dividend. This represents a $1.73 annualized dividend and a dividend yield of 1.03%. The ex-dividend date is Thursday, April 18th. Zoetis’s dividend payout ratio is currently 33.33%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.